IL140801A0 - Method of reducing morbidity and the risk of mortality - Google Patents

Method of reducing morbidity and the risk of mortality

Info

Publication number
IL140801A0
IL140801A0 IL14080101A IL14080101A IL140801A0 IL 140801 A0 IL140801 A0 IL 140801A0 IL 14080101 A IL14080101 A IL 14080101A IL 14080101 A IL14080101 A IL 14080101A IL 140801 A0 IL140801 A0 IL 140801A0
Authority
IL
Israel
Prior art keywords
mortality
risk
reducing morbidity
morbidity
reducing
Prior art date
Application number
IL14080101A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL140801A0 publication Critical patent/IL140801A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14080101A 2000-01-12 2001-01-08 Method of reducing morbidity and the risk of mortality IL140801A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17566300P 2000-01-12 2000-01-12

Publications (1)

Publication Number Publication Date
IL140801A0 true IL140801A0 (en) 2002-02-10

Family

ID=22641136

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14080101A IL140801A0 (en) 2000-01-12 2001-01-08 Method of reducing morbidity and the risk of mortality

Country Status (11)

Country Link
US (1) US20010056099A1 (fr)
EP (1) EP1118323A3 (fr)
JP (1) JP2001226265A (fr)
KR (1) KR100402562B1 (fr)
AU (1) AU1113101A (fr)
CA (1) CA2331059A1 (fr)
CO (1) CO5271696A1 (fr)
HU (1) HUP0100119A3 (fr)
IL (1) IL140801A0 (fr)
PE (1) PE20011120A1 (fr)
ZA (1) ZA200100276B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7178301A (en) * 2000-07-06 2002-01-21 American Home Prod Methods for increasing nitric oxide synthase activity
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US7295691B2 (en) 2002-05-15 2007-11-13 Ge Medical Systems Global Technology Company, Llc Computer aided diagnosis of an image set
JP2005060303A (ja) * 2003-08-12 2005-03-10 Sutaagen:Kk 不動性骨粗鬆の治療または予防剤
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (fr) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Procedes pour le traitement de l'hepatite c
WO2006019832A1 (fr) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines utilisees pour traiter l'hepatite c
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
WO2013090829A1 (fr) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Modulateurs des récepteurs des œstrogènes et ses utilisations
KR20240142622A (ko) 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
LT3386500T (lt) 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3454856B1 (fr) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019006393A1 (fr) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Formes morphiques de git38 et leurs procédés de fabrication
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
KR20220034129A (ko) 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
KR20220119415A (ko) 2019-12-20 2022-08-29 씨4 테라퓨틱스, 인코포레이티드 Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
IL300397A (en) 2020-08-05 2023-04-01 C4 Therapeutics Inc Compounds for targeted knockdown of RET
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
WO2024030968A1 (fr) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Composés pour moduler la protéine ret
WO2024097980A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Inhibiteurs de protéines ret-ldd
EP4611901A1 (fr) 2022-11-04 2025-09-10 Bristol-Myers Squibb Company Agents de dégradation de protéine ret-ldd
EP4735452A2 (fr) 2023-06-30 2026-05-06 Merck Patent GmbH Composés hétérobifonctionnels pour la dégradation de la protéine kras

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція

Also Published As

Publication number Publication date
HUP0100119A3 (en) 2004-04-28
PE20011120A1 (es) 2001-11-05
EP1118323A2 (fr) 2001-07-25
EP1118323A3 (fr) 2003-05-21
JP2001226265A (ja) 2001-08-21
CA2331059A1 (fr) 2001-07-12
KR20010083102A (ko) 2001-08-31
HUP0100119A2 (en) 2002-10-28
HU0100119D0 (en) 2001-03-28
AU1113101A (en) 2001-07-19
US20010056099A1 (en) 2001-12-27
CO5271696A1 (es) 2003-04-30
KR100402562B1 (ko) 2003-10-17
ZA200100276B (en) 2002-07-10

Similar Documents

Publication Publication Date Title
HU0100119D0 (en) Method of reducing morbidity and the risk of mortality
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
AU9667901A (en) Mycoattractants and mycopesticides
GB2368600B (en) Well planning and design
SG114454A1 (en) Laser dermablator and dermablation
EP1299168A4 (fr) Biocollecteur et concentrateur a mini-cyclones
EP1313477A4 (fr) Composes et procedes
EP1274424A4 (fr) Composes et procedes
PL373846A1 (en) Method of reducing mortality and morbidity associated with critical illnesses
GB0014580D0 (en) Appatarus and process
GB0028589D0 (en) Optical devices and methods
EP1343796A4 (fr) Composes et procedes
GB0114047D0 (en) Methods and assemblies
GB2376970B (en) Well planning and design
GB2347612B (en) Wrist and hand support
GB2364764B (en) Hand and wrist support
GB2363981B (en) Assemblies of Case-holder and Case
GB0008876D0 (en) IC2CU and IC2IDU
GB0029496D0 (en) Optipouch and optipad
GB0005892D0 (en) Computer applicatyion develoopement and deployment
TW437782U (en) Joint structure between H-column and C-beam
GB0121553D0 (en) Edging-slabs and methods using them
GB0026090D0 (en) Slot-ons- fitments and shades
GB0026657D0 (en) The dynowheel and its components
GB2391470B (en) Assemblies of Case-Holder and Case